The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.

CAR-T pipeline advances, with blood cancers at the forefront of development, driving new treatment innovations.

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...

While the allogeneic vs autologous debate continues in the cell therapy field, research on in vivo therapies is drawing ...

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

Novartis’ Kymriah has become the first CAR-T available to NHS patients across the UK after Scotland’s medicines cost-effectiveness body recommended funding in an aggressive form of lymphoma.

Legend Biotech), tisagenlecleucel (Kymriah, Novartis), brexucabtagene autoleucel (Tecartus, Kite Pharma/Gilead Sciences) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead Sciences).

Who Are the Key Players in the Kymriah Market? The Kymriah market is dominated by Novartis AG, a key player in CAR-T cell therapy innovation. Advancements in Kymriah and other CAR-T therapies have ...

A total of 1,693 shareholders were present at the meeting held in Basel, representing approximately 57.42% of the issued shares of Novartis. With a dividend increase of 6.1% to CHF 3.50 per share, ...

The drugmaker actually managed to get approval for funding in DLBCL ahead of Kymriah, but Novartis’ drug was also backed in this form of NHL earlier this year, setting the two CAR-Ts up for head ...